Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects

• Main Authors: Sufeng Zhou (Author), Lijun Xie (Author), Chen Zhou (Author), Lu Wang (Author), Juan Chen (Author), Sijia Ding (Author), Bei Zhu (Author), Mei Su (Author), Feng Shao (Author)
• Format: Book
• Published: Wiley, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and pharmacodynamics (PDs) of multiple doses of keverprazan. This was a randomized, positive‐/placebo‐controlled, phase Ic...